Cargando…
P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430911/ http://dx.doi.org/10.1097/01.HS9.0000971492.92995.27 |
| _version_ | 1785091073115160576 |
|---|---|
| author | Rosenthal, Allison Jun, Monika Munoz, Javier Wang, Tongsheng Mutebi, Alex Wang, Anthony Yang, Shibing Osei-Bonsu, Kojo Elliott, Brian Kalsekar, Anupama Rivas Navarro, Fernando Ip, Andrew |
| author_facet | Rosenthal, Allison Jun, Monika Munoz, Javier Wang, Tongsheng Mutebi, Alex Wang, Anthony Yang, Shibing Osei-Bonsu, Kojo Elliott, Brian Kalsekar, Anupama Rivas Navarro, Fernando Ip, Andrew |
| author_sort | Rosenthal, Allison |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10430911 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-104309112023-08-17 P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS Rosenthal, Allison Jun, Monika Munoz, Javier Wang, Tongsheng Mutebi, Alex Wang, Anthony Yang, Shibing Osei-Bonsu, Kojo Elliott, Brian Kalsekar, Anupama Rivas Navarro, Fernando Ip, Andrew Hemasphere Posters Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10430911/ http://dx.doi.org/10.1097/01.HS9.0000971492.92995.27 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Rosenthal, Allison Jun, Monika Munoz, Javier Wang, Tongsheng Mutebi, Alex Wang, Anthony Yang, Shibing Osei-Bonsu, Kojo Elliott, Brian Kalsekar, Anupama Rivas Navarro, Fernando Ip, Andrew P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title | P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title_full | P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title_fullStr | P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title_full_unstemmed | P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title_short | P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS |
| title_sort | p1149: comparison of the efficacy of epcoritamab versus chimeric antigen receptor therapies, polatuzumab-based regimens, and tafasitamab-based regimens |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430911/ http://dx.doi.org/10.1097/01.HS9.0000971492.92995.27 |
| work_keys_str_mv | AT rosenthalallison p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT junmonika p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT munozjavier p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT wangtongsheng p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT mutebialex p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT wanganthony p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT yangshibing p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT oseibonsukojo p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT elliottbrian p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT kalsekaranupama p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT rivasnavarrofernando p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens AT ipandrew p1149comparisonoftheefficacyofepcoritamabversuschimericantigenreceptortherapiespolatuzumabbasedregimensandtafasitamabbasedregimens |